[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643880":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":24,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":24,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":24,"enrollmentInfo":63,"targetDuration":24,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group HA","EXPERIMENTAL","Patients will be given intra-articular injection of 2 ml of hyaluronic acid into the joint space three times weekly.",[13],"Drug: Hyaluronic acid",{"label":15,"type":10,"description":16,"interventionNames":17},"Group BTX","Patients will be given intra-articular injection of 100 units of Botulinum toxin type A, diluted with 5 ml of normal saline three times weekly.",[18],"Drug: Botulinum toxin type A",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Hyaluronic acid",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Botulinum toxin type A",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Mohammed S ElSharkawy, MD","CONTACT","00201148207870","mselsharkawy@med.tanta.edu.eg",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.00192,30.78847,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":32,"phoneExt":24,"email":33},"Mohammed S Elsharkawy, MD",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Mohammed Said ElSharkawy","Lect urer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.","100643880","intraarticular-injection-of-botox-and-hyaluronic-acid-in-knee-osteoarthritis-100643880",false,"NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.","ALL","50 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"NA","This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[71,72,73,74],"Intraarticular Injection","Botox","Hyaluronic Acid","Knee Osteoarthritis","2026-06-24",{"date":77,"type":78},"2026-06-25","ACTUAL",{"date":75,"type":78},{"date":81,"type":65},"2026-12-01",{"name":5,"class":6},1]